이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clinomics 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

ByungChul Kim

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	0.01%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Benign Growth For Clinomics Inc. (KOSDAQ:352770) Underpins Stock's 33% Plummet

Mar 15

CEO

ByungChul Kim (59 yo)

no data

테뉴어

Mr. ByungChul Kim serves as Chief Executive Officer of Clinomics Inc. He is Genetics Expert. He has been ommercialized Asia’s first personalized genome analysis product (Theragen Etex HelloGene); Developed...

Clinomics 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Clinomics Inc., Annual General Meeting, Mar 24, 2021

Recent updates

New major risk - Share price stability

Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million.

Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million.

Clinomics Inc. has filed a Follow-on Equity Offering in the amount of KRW 999.999932 million.

Clinomics Inc. announced that it has received KRW 4 billion in funding

Benign Growth For Clinomics Inc. (KOSDAQ:352770) Underpins Stock's 33% Plummet

New major risk - Revenue and earnings growth

New major risk - Share price stability

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2022 earnings released: ₩768 loss per share (vs ₩1,214 profit in FY 2021)

Investor sentiment improves as stock rises 23%

Clinomics Inc. announced that it expects to receive KRW 2.99999694 billion in funding

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS ₩354 (vs ₩289 loss in 3Q 2020)

Clinomics Inc., Annual General Meeting, Mar 24, 2021

CEO

테뉴어